- Home
- PMO vs BWAY Comparison
PMO vs BWAY Comparison
Compare PMO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- BWAY
- Stock Information
- Founded
- PMO 1993
- BWAY 2003
- Country
- PMO United States
- BWAY Israel
- Employees
- PMO N/A
- BWAY N/A
- Industry
- PMO Finance Companies
- BWAY Medical/Dental Instruments
- Sector
- PMO Finance
- BWAY Health Care
- Exchange
- PMO Nasdaq
- BWAY Nasdaq
- Market Cap
- PMO 287.6M
- BWAY 280.7M
- IPO Year
- PMO N/A
- BWAY 2019
- Fundamental
- Price
- PMO $10.27
- BWAY N/A
- Analyst Decision
- PMO
- BWAY Strong Buy
- Analyst Count
- PMO 0
- BWAY 2
- Target Price
- PMO N/A
- BWAY $18.00
- AVG Volume (30 Days)
- PMO 99.0K
- BWAY 61.1K
- Earning Date
- PMO 01-01-0001
- BWAY 11-11-2025
- Dividend Yield
- PMO 4.10%
- BWAY N/A
- EPS Growth
- PMO N/A
- BWAY 679.98
- EPS
- PMO 0.42
- BWAY 0.11
- Revenue
- PMO N/A
- BWAY $46,084,000.00
- Revenue This Year
- PMO N/A
- BWAY $335.63
- Revenue Next Year
- PMO N/A
- BWAY $22.10
- P/E Ratio
- PMO $24.38
- BWAY $55.30
- Revenue Growth
- PMO N/A
- BWAY 26.50
- 52 Week Low
- PMO $8.57
- BWAY $7.84
- 52 Week High
- PMO $10.68
- BWAY $17.00
- Technical
- Relative Strength Index (RSI)
- PMO 50.04
- BWAY 51.50
- Support Level
- PMO $9.80
- BWAY $14.61
- Resistance Level
- PMO $10.50
- BWAY $15.60
- Average True Range (ATR)
- PMO 0.10
- BWAY 0.66
- MACD
- PMO -0.03
- BWAY -0.12
- Stochastic Oscillator
- PMO 9.37
- BWAY 41.78
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.